Analyst Price Target is $12.17
▲ +1,601.63% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Reunion Neuroscience in the last 3 months. The average price target is $12.17, with a high forecast of $20.00 and a low forecast of $5.50. The average price target represents a 1,601.63% upside from the last price of $0.72.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Reunion Neuroscience.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.